curriculum vitae › cv › ford.pdf · 2011-10-04 · october 4, 2011 curriculum vitae name:...

October 4, 2011

CURRICULUM VITAE

NAME: Charles Erwin Ford, Ph.D. Title: Associate Professor of Biostatistics

OFFICE ADDRESS: The University of Texas Health Science Center at HoustonSchool of Public Health1200 Herman Pressler Dr., Room W-940Houston, Texas 77030(713) 500-9513; Fax: (713) 500-9530;Internet: [email protected]

EDUCATION:

1986 Ph.D., Biostatistics, The University of Texas-Houston School of Public HealthDissertation: Polychotomous Logistic Regression Analysis

1981 M.S., Biostatistics, The University of Texas-Houston School of Public HealthThesis:The Use of a Categorical Model to Examine the Effect of Pre-existingEnd-Organ Damage on the Pharmacologic Control of Hypertension

1969 B.S., Mathematics, University of Central Oklahoma

PROFESSIONAL EXPERIENCE & RESEARCH:Academic:

1995- Associate Professor of Biostatistics, The University of Texas Health ScienceCenter at Houston (UTHSC), School of Public Health (UTSPH)

1986-95 Assistant Professor of Biostatistics, The University of Texas-Houston HealthScience Center, School of Public Health

Service:2010-11 Admissions Representative, Biostatistics Division.

2005-11 Member (Currently, Committee Chair), Nominating Committee, UTHSCstanding committee.

2003-10 Abstract Reviewer, American Heart Association annual scientific meeting.

2002-03 Judge, National Youth Leadership Forum on Medicine.

2000-02 Member SPH Admissions Committee, representing Disease Control Module

1997-99 Member Interfaculty Council, The University of Texas Heath Science Center

1995-00 Co-Director, Conference on Career Opportunities in Public Health forMathematics and Science Majors. The Conference goal is to increase thenumber of well qualified applicants to graduate programs at the School ofPublic Health by informing undergraduate faculty from colleges anduniversities in Texas and surrounding states about public health and careeropportunities for their students.

1994-00 Member Academic Computing Committee, UTHSC standing committee.

October 4, 2011 Charles E. Ford 2

1992-96 Member, Information Resources Steering Team, UTHSC -- Special standingUTHSC committee to review information resources and needs at UT-HoustonHealth Science Center for strategic planning.

1988-07 Member, Biostatistics Admissions Committee

Research:2011- Co-Investigator, TCD With Transfusions Changing To Hydroxyurea (TWITCH):

subcontract award ($2,849,856) from St. Jude Hospital for Data CoordinatingCenter (DCC) for an NHLBO sponsored clinical trial.

2008- Co-Principal Investigator, Clinical Trials Center for the Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): contactaward ($88 million) from the National Heart, Lung, and Blood Institute. BarryR. Davis is the principal investigator at UTSPH.

2007-2009 Principal Investigator, The Enigma of Placebo Adherence and HealthOutcomes, Kaiser Foundation Research Institute subaward to contract R01HL081195. $55,600.

2006-2008 Principal Investigator, Clinical Trials Center for the Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): contactaward ($88 million) from the National Heart, Lung, and Blood Institute. ALLHAT is a large-scale, double-blind, multicenter, clinical trial in 625 centersthroughout the United States and Puerto Rico to test the effectiveness of fourantihypertensive agents in reducing the incidence of coronary heart disease in40,000 patients 55 years of age and older with diastolic and/or systolichypertension. A second, nested clinical trial will test the effectiveness of anHMG-CoA reductase inhibitor in reducing mortality in 20,000 of thesepatients.

2006- Principal Investigator, Genetics of Hypertension Associated Treatments(GenHAT), National Heart, Lung, and Blood Institute, R01 Grant Renewal($745,500) for three years. Original 5-year grant ($981,516) was fundedthrough the University of Minnesota where the principal investigator waslocated. Barry Davis was former UTSPH principal investigator. Total originalgrant for the three participating groups was $4,651,890; Dr. Eric Boerwinkle(UTSPH) was also funded as part of this grant. Each of the other threeparticipating Principal Investigators now have their own renewed funding (~$4million). The group will continue to study genotype-treatment interactions inthe treatment of hypertension, using data and DNA samples from the 42,418participants in ALLHAT.

2003-2005 Principal Investigator, Preparation of Limited Access Data Sets for theHypertension Detection and Follow-up Program (HDFP) and the SystolicHypertension in the Elderly Program (SHEP), National Heart, Lung, and BloodInstitute (NHLBI), contract N02-HL-3-4 ($134,749). A limited access data setand supporting documentation for two major NHLBI clinical trials, HDFP andSHEP, was developed and delivered to NHLBI. These data sets and theirdocumentation meet current NHLBI and HIPPA confidentiality anddocumentation requirements.


2001-2003 Co-Investigator, Genetics of Angioedema, Bristol-Meyer Squibb Company,contract ($2 million). Principal Investigator: Eric Boerwinkle (UTSPH). Genetic sequencing and genotyping of candidate genes possibly related tothe development of angioedema in the treatment of hypertension.

1999-2006 Co-Principal Investigator, Genetics of Hypertension Associated Treatments(GenHAT), National Heart, Lung, and Blood Institute, R01 grant ($981,516)funded through the University of Minnesota where the principal investigator islocated. Barry Davis is the UTSPH principal investigator. Total grant for thethree participating groups is $4,651,890; Dr. Eric Boerwinkle (UTSPH) wasalso funded as part of this grant. The group will study genotype-treatmentinteractions in the treatment of hypertension, using data and DNA samplesfrom the 42,418 participants in ALLHAT (see below).

1993-2006 Co-Investigator, Clinical Trials Center for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): contact award($88 million) from the National Heart, Lung, and Blood Institute. Barry R.Davis is the principal investigator at UTSPH.

1994-1995 Principal Investigator, Renal Cell Carcinoma Incidence in PatientsReceiving Antihypertensive Pharmacologic Treatment, Merck ResearchLaboratories, $3,000. Analyses were carried out at the request of Merckscientists on the 6.5-year incidence of renal cell carcinoma (fatal and nonfatal)among the 10,940 participants in the Hypertension Detection and Follow-upProgram (HDFP).

1991-1995 Principal Investigator, subcontract to A Prospective Study of Blood Pressureand ESRD, Johns Hopkins University, R01 grant ($69,750) funded throughthe NIH's National Institute of Diabetes and Digestive and Kidney Diseases(NIDDK). Data on 159,000 screenees for the Hypertension Detection andFollow-up Program are being compared with data from the Health CareFinance Administration's End-Stage Renal Disease (ESRD) Programdatabase to investigate the relationship between blood pressure and theincidence of ESRD in a prospective, community-based sample of the U.S.ambulatory population.

1991-1995 Co-Director, Training Grant for Career Opportunities in Biostatistics andPublic Health for Science Majors, Bureau of Health Professions, U.S. PublicHealth Service. Summer conferences on career opportunities in biostatisticsand public health for science majors were held on three consecutive summersat UTSPH. Conference participants were selected through competitiveapplication from the science and math faculty of undergraduate institutions inTexas and surrounding states. Conference goal is to increase the number ofqualified applicants to graduate programs in biometry and biostatistics,particularly the School of Public Health's Biometry Program.

1986-1995 Co-Principal Investigator, Extended Analyses in the Hypertension andDetection and Follow-up Program (HDFP) — Risks and Benefits: R01 grant($727,358) from the National Heart, Lung, and Blood Institute. Extendedmortality surveillance of the HDFP population though the National DeathIndex and Social Security Administration. Risk factors for long-term mortalityamong persons with hypertension are being studied as well as the long-term


benefits from effective pharmacologic control of high blood pressure in thiscohort of 25,000 participants screened in 14 centers in 1973 to 1974. Mortality follow-up is being extended through 1987.

1978-1986 Biostatistician, Coordinating Center for Clinical Trials, The University ofTexas-Houston School of Public Health. Responsible for data analysis,quality control, monitoring, and reporting of NHLBI funded large-scale,multicenter, cardiovascular clinical trials.

1977-1978 Senior Systems Analyst/Director of Computer Programming,Hypertension Detection and Follow-up Program (HDFP) (NHLBI contract;$15.9 million) and the Beta-Blocker Heart Attack Trial (BHAT) (NHLBIcontract; $4.1 million). These two large-scale, multicenter clinical trials areamong the largest clinical trials ever conducted through funding from theNHLBI. The databases for these two studies were composed of hundreds ofmillions of data items and were efficiently managed and analyzed at theCoordinating Center for Clinical Trials, The University of Texas-HoustonSchool of Public Health.

1974-1977 Senior Systems Analyst/Programmer, Coordinating Center for ClinicalTrials, The University of Texas-Houston School of Public Health. Responsiblefor the design and implementation of data systems for management andanalysis of large-scale, multicenter clinical trials.

1971-1974 Data Systems Programmer/Analyst, Lockheed Electronics Company, Inc.,Houston Aerospace Systems Division. Participated as part of theprogramming team responsible for the design and implementation ofinteractive information management systems for the National Aeronautics andSpace Administration's (NASA) Crew Procedures and Flight Control Divisions,and provided mathematical and statistical analysis support for theComputational and Analysis Division, National Aeronautics and SpaceAdministration, L. B. Johnson Space Center, Houston, Texas.

1969-1971 Computer Programming Specialist, United States Army, with service inVietnam (1970-1971). Developed and maintained the informationmanagement system and database for U.S. Army personnel in Vietnam.

1969 Associate Scientist, Lockheed Electronics Company, Inc., HoustonAerospace Systems Division. Conducted trajectory and orbital error analysisfor Apollo Space Program.

Professional Consulting:

2011 National Heart, Lung, and Blood Institute: Special Review Panel for “ProgramProject Grant--Mineralocorticoid Receptor: Role in Cardiovascular Disease.”

2009-2009 Baylor College of Medicine, Houston, Texas. Member DSMB for “Effect ofLipid Modification on Peripheral Arterial Disease after EndovascularIntervention (ELIMIT).”


2008-09 The University of Texas Southwestern, Division of Hypertension, Dallas, Texas. Pediatric Trial of Preventing Hypertension (Pedi-TROPHY) Trial, ScientificAdvisory Board.

2007-09 National Institute of Diabetes and Digestive and Kidney Diseases: Data andSafety Monitoring Board for “The AASK Ambulatory BP Pilot Study: TheEffect of Ramipril-Based Antihypertensive Therapies on Nocturnal BP.”

2006 BioMarin Pharmaceutical, Inc., Novato, CA: Data and Safety Monitoring Board, APhase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, ParallelStudy of the Effects of 6R-BH4 (sapropterin dihydrochloride) on BloodPressure in Subjects With Poorly Controlled Systemic Hypertension.

2004 National Institute of Diabetes and Digestive and Kidney Diseases: Site visit teamfor the CRIC Data Coordinating Center Chronic Renal Insufficiency Cohort(CRIC), November 4, 2004.

2002 National Institute of Diabetes and Digestive and Kidney Diseases: Review groupfor “Polycystic Kidney Disease Clinical Trials Network.”

2001 National Institute of Diabetes and Digestive and Kidney Diseases: Review groupfor “Minimally Invasive Surgical Therapies Treatment Consortium for BenignProstatic Hyperplasia.”

2001 National Institute of Diabetes and Digestive and Kidney Diseases: Review groupfor “Technical Support for the NIDDK Epidemiology Coordinating Committee.”

2000 Wake Forest University School of Medicine, Review group for “Selection ofElectrocardiogram Reading Center for the Study of Health Outcomes ofWeight Loss (SHOW).”

1998 Baylor College of Medicine, Department of Family and Community Medicine:“Impact of Improved Hypertension Control on Morbidity and Mortality in aLow-Income, African-American Clinic Population.”

1995 National Institute of Diabetes and Digestive and Kidney Diseases: Ad HocReview Group for “Epidemiology of Diabetes Interventions and Complications(EDIC) Study — Clinical Coordinating Center and Data Coordinating Center.”

1994-01 National Institute of Diabetes and Digestive and Kidney Diseases: MemberExternal Advisory Committee for “The African-American Study of KidneyDisease and Hypertension (AASK).”

1992-94 National Institute of Diabetes and Digestive and Kidney Diseases: MemberExternal Advisory Committee for “The African-American Study of KidneyDisease and Hypertension (AASK) Pilot Study.”

1992-94 Johns Hopkins University, School of Public Health and Medical School: “Relationship of early and late changes in renal function to end-stage renaldisease;” with Gordon Walker, M.D.

1991-92 University of Nevada Medical School, Reno, Nevada: Biostatistics consultant for“Characteristics and possible risk factors associated with chronic fatigue


syndrome in Northern Nevada.” and “Proposal for clinical center for thePeripheral Arterial Disease (PAD) pilot study to evaluate treatment andprevention strategies for atherosclerotic cardiovascular disease.”

1988-93 Harris County Health Department and Houston City Health Department: “AIDS projections for Harris County and Houston.”

1991-91 National Institute on Aging: Claude Pepper Centers Ad Hoc Review Committee

1990-90 National Institute of Diabetes and Digestive and Kidney Diseases: Workshop onKidney Disease and Hypertension in Blacks

1990-90 National Heart, Lung, and Blood Institute: Workshop on serum cholesterol andCHD in women and the elderly.

1990-90 MRC/ICRF Clinical Trial Service Unit, Nuffield Department of Clinical Medicine,Radcliffe Infirmary, Oxford, UK (Richard Peto): “Blood pressure, stroke, andcoronary heart disease.”

1989-90 Medical College of St. Bartholomew's Hospital, London, England (Malcom Law): “Relationship of serum cholesterol and cancer.”

1989-90 Duke University Medical Center Hospital, Director of Laboratories: “Statisticaldesign of biochemistry research studies of cholesterol and hyperglycemia.”

1989-90 National Heart, Lung, and Blood Institute: Working Group on Renal Disease andHypertension

1989-89 Ciba-Geigy Corporation: “Urinary biochemical profile and survival of personswith declining renal function.”

1988-90 The Johns Hopkins Medical Institutions, Welch Center for Prevention,Epidemiology & Clinical Research: “Development of research designs forstudying end-stage renal disease incidence and prevention.”

1988-88 University of Nevada Medical School, Reno, Nevada: “Design of biostatisticscurriculum for medical students.”

1979-81 Marion Laboratories, Inc., Kansas City, Missouri: “Statistical analysis and dataquality assurance for a controlled, double-blind, Phase III clinical trialevaluating the efficacy and safety of a new antidepressant drug: Dothiepinhydrochloride.”

RESEARCH INTERESTS:

Biometry/biostatistics; design, conduct and analysis of multicenter clinical trials; geometry ofmultivariate analysis; statistical computing; multiple endpoints analysis; longitudinal dataanalysis; polychotomous logistic regression analysis; chronic diseases; cardiovascular disease,hypertension, end-stage renal disease, diabetes; genetics of hypertension and itspharmacologic treatment.


AWARDS & HONORS:2002-2003 International and National Honors in Research Award, The University of Texas

Health Science Center at Houston, 2003; for ALLHAT which received recognition fromthe American Heart Association’s top 10 research advances for 2002 and for the journalarticle describing findings in this landmark clinical study which was recognized by theThomson-ISI Web of Science database as “one of the most cited recent papers in thefield of clinical medicine.”

American Men & Women of Science, 1994, 2000, 2010Outstanding Scholarship Award, The University of Texas Health Science Center at Houston,

1994Outstanding Achievement in Sponsored Research Award, The University of Texas Health

Science Center at Houston, 1994; for the Antihypertensive and Lipid-LoweringTreatment to Prevent Herat Attack Trial (ALLHAT) Clinical Trials Center — "LargestContract Ever Received by UT-Houston"

Outstanding Faculty Award, The University of Texas Health Science Center at Houston,1993

Fellow, American Heart Association Council on Prevention and Epidemiology, 1989

PROFESSIONAL AFFILIATIONS:American Heart Association Council on Epidemiology, FellowAmerican Statistical AssociationBiometrics SocietyHouston Area Chapter of the American Statistical AssociationInstitute of Mathematical StatisticsSociety for Clinical TrialsSociety for Epidemiologic Research

COURSES TAUGHT:Foundations of BiostatisticsIntermediate Biostatistical Methods I and IIMultivariate Analysis I and II Statistical Programming I and IIStatistical Theory of Biostatistics (Mathematical Statistics)

LECTURERS GIVEN IN:Statistical Methods in Clinical TrialsEpidemiology & Prevention of Cardiovascular DiseaseAdvanced Epidemiologic Methods

Design of ExperimentsIntroduction to Program EvaluationDesign & Conduct of Disease Intervention Clinical Trials

TOPICS OF SUPERVISED INDIVIDUAL STUDIES:Multivariate AnalysisGeneral Linear ModelsStatistical Computing & Programming ConceptsAdvance Algorithms for Statistical AnalysesSample Size Algorithms and ComputationDifferential & Integral CalculusLinear Algebraic AnalysisSpecial Topics in Disease ControlSpecial Topics in Biostatistics


APPOINTMENTS & COMMITTEE MEMBERSHIP:

! Steering Committee for the Antihypertension and Lipid-Lowering Treatment to PreventHeart Attack Trial (ALLHAT), (2006-present)

! Nominating Committee, The University of Texas-Houston Health Science Center(UTHSC), (2005-2011)

! SPH Admissions Committee, (2000-2002, 2010-2011)

! UTHSC Interfaculty Council, (1998-2000)

! UTHSC Interfaculty Council Subcommittee on Teaching Effectiveness, (1998-1999)

! Steering Committee for the Genetics of Hypertension Associated Treatments (GenHAT), (1998-present)

! Endpoints Committee, Antihypertension and Lipid-Lowering Treatment to Prevent HeartAttack Trial (ALLHAT) (1996-2002)

! Medical Management Committee, Antihypertension and Lipid-Lowering Treatment toPrevent Heart Attack Trial (ALLHAT), (1998-2002)

! Publications Committee, Antihypertension and Lipid-Lowering Treatment to PreventHeart Attack Trial (ALLHAT), (1994-present)

! Ad Hoc committee on Strategic Planning for Information Resources, The University ofTexas-Houston Health Science Center (UTHSC), President Low, Chair, (1994) —Review issues and stimulate strategic alternatives regarding the needs of UT-Houstonfor information resources in the near future.

! Scientific and Educational Programs Committee, Antihypertension and Lipid-LoweringTreatment to Prevent Heart Attack Trial (ALLHAT) (1994-2002)

! Quality Control Committee, Antihypertension and Lipid-Lowering Treatment to PreventHeart Attack Trial (ALLHAT) (1994-2002)

! External Advisory Committee for National Institute of Diabetes and Digestive and KidneyDiseases' (NIDDK) African-American Study of Kidney Disease and Hypertension(AASK), (1994-2001)

! External Advisory Committee for NIDDK's African-American Study of Kidney Diseaseand Hypertension (AASK) Pilot Study, (1992-1994)

! Claude Pepper Centers Ad Hoc Review Committee, National Institute on Aging, (1991)

! National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Workshopon Kidney Disease and Hypertension in Blacks, (1990)

! National Heart, Lung, and Blood Institute (NHLBI): Workshop on serum cholesterol andCHD in women and the elderly, (1990)

! Disease Control Admissions Committee, UTSPH (1988-2003)

! UTSPH Faculty Merit Review Committee, UTSPH (1987)

! Editorial Review and Publications Committee, Hypertension Detection and Follow-upProgram (HDFP), (1986-1994)


PUBLICATIONS (* indicates students):

1. Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Ford CE, Oparil S, ProbstfieldJL, Whelton PK, Wright JT, Jr, Alderman MH, Basile JN, Black HR, Grimm RH, Jr,Hamilton BP, Haywood LJ, Ong ST, Piller LB, Simpson LM, Stanford C, Weiss RJ, for theALLHAT Collaborative Research Group. Mortality and Morbidity during and after theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J ClinicalHypertension 2011 (In Press). (PMCID: )

2. Piller LB, Baraniuk S, Simpson LM, Cushman WC, Massie BM, Einhorn PT, Oparil S, FordCE, Graumlich JF, Dart RA, Parish DC, Retta TM, Cuyjet AB, Jafri SZ, Furberg CD,Saklayen MG, Thadani U, Probstfield JL, Davis BR. Long-term follow-up of participantswith heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent HeartAttack Trial (ALLHAT). Circulation 2011 (In Press). (PMCID: )

3. Tanner RM, Lynch AI, Brophy VH, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, ArnettDK. Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovasculardisease in patients with hypertension. PLoS ONE 2011; 6(8): e23609. (PMCID: )

4. Nguyen* DTM, Hung NQ, Giang LT, Dung NH, Lan NTNL, Lan NN, Yen NTB, Bang ND,Ngoc DV, Trinh LTT, Beasley RP, Ford CE, Hwang LY, Graviss EA. Improving thediagnosis of pulmonary tuberculosis in HIV-infected individuals in Ho Chi Minh City,Vietnam. The International Journal of Tuberculosis and Lung Disease 2011 (In Press).

5. Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogeneticeffect of the stromelysin (MMP3) polymorphism on stroke risk in relation toantihypertensive treatment: The GenHAT Study. Stroke 2011;42;330-335. (PMCID: )

6. Margolis KL, Dunn K, Simpson LM, Ford CE, Williamson JD, Gordon DJ, Einhorn PT,Probstfield JL, for the ALLHAT Collaborative Research Group. Coronary heart disease inmoderately hypercholesterolemic, hypertensive black and non-black patients randomizedto pravastatin versus usual care: The Antihypertensive and Lipid-Lowering to Prevent HeartAttack Trial (ALLHAT-LLT). Am Heart J 2009;158:948-955. (PMCID2904958)

7. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A, for theALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-upin ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54:2023-2031. (PMCID: )

8. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A oncardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenetics and Genomics 2009; 19:415-421. (PMCID2764310)

9. Wright JT Jr, Probstfield JL, Cushman WC, Pressel S, Cutler JA, Davis BR, Einhorn PT,Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR,Alderman MH, for the ALLHAT Collaborative Research Group. ALLHAT findings revisitedin the context of subsequent analyses, other trials and meta-analyses. Archives InternMed 2009; 169:832-842. (PMCID2803011)

10. Maitland-van der Zee AH, Peters BJ, Lynch AI, Boerwinkle E, Arnett DK, Cheng S, DavisBR, Leiendecker-Foster C, Ford CE, Eckfeldt JH. The effect of nine commonpolymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectivenessof statins: the GenHAT study. Pharmacogenetics and Genomics 2009; 19:338-344.(PMCID2701506)


11. Cushman WC, Ford CE, Einhorn PT, Wright JT, Preston RA, Davis BR, Basile JN,Whelton PK, Weiss RJ, Bastien A, Courtney DL, Hamilton BP, Kirchner K, Louis GT, RettaTM, Vidt DG, for the ALLHAT Collaborative Research Group. Blood pressure control bydrug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackTrial (ALLHAT). J Clin Hypertens 2008; 10:751-760. (PMCID2897821)

12. Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, FordCE, Levy D, Massie BM, Shah Nawaz S, for the ALLHAT Collaborative Research Group. Heart failure with preserved and reduced left ventricular ejection fraction in ALLHAT. Circulation 2008; 118:2259-2267. (PMCID2775475)

13. Maitland-van der Zee AH, Lynch A, Boerwinkle E, Arnett DK, Davis BR,Leiendecker-Foster C, Ford CE, Eckfeldt JH. Interactions between the single nucleotidepolymorphisms in the homocysteine pathway (MTHFR 677C> T, MTHFR 1298 A> C, andCBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovasculardisease in high-risk patients of hypertension: the GenHAT study. Pharmacogenetics andGenomics 2008; 18:651–656.(PMCID2729516)

14. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK.Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovasculardisease outcomes in patients with hypertension. JAMA 2008; 299:296-307. (PMID:18212314)

15. Liu* L, Coker AL, Du XL, Cormier JN, Ford CE, Fang S. Long-term survival after radicalprostatectomy compared to other treatments in older men with local/regional prostatecancer. Journal of Surgical Oncology 2008; 97:583-591.

16. Margolis KL, Piller LB, Ford CE, Henriquez MA, Cushman WC, Einhorn PT, Colon PJ Sr,Vidt DG, Christian R, Wong ND, Wright JT Jr, Goff DC Jr, and ALLHAT CollaborativeResearch Group. Blood pressure control in Hispanics in the Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension 2007; 50:854-861.

17. Lynch AI, Arnett DK, Davis BR, Boerwinkle E, Ford CE, Eckfeldt JH, Leiendecker-Foster C.Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months onantihypertensive treatment: The GenHAT study. Annals of Human Genetics 2007; 71:735-745. (PMID: 17608790)

18. Maitland-van der Zee AH, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, MillerMB, Klungel OH, Ford CE, Eckfeldt JH. Absence of an interaction between the angiotensinconverting enzyme (ACE) insertion-deletion polymorphism and pravastatin oncardiovascular disease in high-risk hypertensives: The GenHAT Study. Am Heart J 2007;153:54-58. (PMID: 17174637)

19. Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, Black H,Eckfeldt JH. Antihypertensive therapy, the alpha-adducin polymorphism, andcardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. The Pharmacogenomics J 2007; 7:112-122. (PMID:16702981)

20. Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL,for the ALLHAT Collaborative Research Group. Incidence and predictors of angioedema inelderly hypertensive patients at high risk for cardiovascular disease: A report from theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JClin Hypertens 2006; 8:649-656.

21. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H,Eckfeldt JH. Pharmacogenetic association of the enzyme insertion/deletion polymorphism


on blood pressure and cardiovascular risk in relation to antihypertensive treatment: TheGenetics of Hypertension-Associated Treatment (GenHAT) Study. Circulation 2005;111:3374-3383. (PMID: 15967849)

22. Wright JT, Dunn K, Cutler J, Davis BR, Cushman WC, Ford CE, Haywood LJ, LeenenFHH, Margolis K, Papademetriou V, Probstfield JL, Whelton PK, Habib GB, for theALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblackpatients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293:1595-1608. (PMID: 15811979)

23. Lusk CM, Bettencourt J, Carroll L, Egan D, Ford C, Kingry C, Johnson J, Sullivan S,Nwachuku C, Probstfield JL. The ALLHAT Adherence Survival Kit. Applied Clinical Trials2004; 13:40-48.

24. Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black H. Imputing gene-treatmentinteractions when the genotype distribution is unknown using case-only and putativeplacebo analyses -- A new method for the Genetics of Hypertension Associated Treatment(GenHAT) Study. Statistics in Medicine 2004; 23:2413-2427. (PMID: 15273956)

25. Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, Reison E,Sumner BM, Wong ND, Nwachuku C, Narayan P, Haywood LJ, Habib G. Characteristicsand lipid distribution of a large, high-risk, hypertensive population: The lipid-loweringcomponent of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackTrial (ALLHAT). J Clin Hypertens 2003; 5:377-385. (PMID: 14688492)

26. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Diuretic versus a-blocker as first-step antihypertensive therapy. Final results from theAntihypertensive and Lipid-Lowering Treatment to Prevent Herat Attack Trial (ALLHAT). Hypertension 2003; 42:239-246. (PMID: 12925554)

27. Gorham* RA, Emery RJ, Ford CE, Cooper SP. Statistical validation of a commonly usedmethod for personnel dosimetry issuance determinations. Health Physics 2003; 84:260-265.

28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-convertingenzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997. (PMID: 12479763)

29. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized topravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to PreventHeart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007. (PMID: 12479764)

30. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, HamiltonBP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH,Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT Collaborative ResearchGroup. Success and predictors of blood pressure control in diverse North Americansettings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT). J Clin Hypertens 2002; 4:393-404. (PMID: 12461301)

31. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogeneticapproaches to hypertension therapy: design and rationale for the Genetics of HypertensionAssociated Treatment (GenHAT) study. The Pharmacogenomics Journal 2002; 2:309-317.(PMID: 12439737)


32. Cooksley* CD, Hwang LY, Ford CE. HIV and cancer: Community-based analysis of trendsand registry linkage. J Registry Management 2001; 28:82-87.

33. Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J,Alderman MH, Basile JN, Black HR, DeQuattro V, Echfeldt J, Hawkins CM, Proschan M,for the ALLHAT Collaborative Research Group. Baseline characteristics of the 42,448 highrisk hypertensives enrolled in the Antihypertensive and Lipid-Lowering Treatment toPrevent Heart Attack Trial (ALLHAT). Hypertension 2001; 37:19:27. (PMID: 11208751)

34. Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J,Kimmel B, Lusk C, parks H, Simpson LM, Nwachuku C, Furberg CD, for the ALLHATCollaborative Research Group. Operational aspects of terminating the doxazosin arm ofthe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT). Controlled Clinical Trials 2001; 22:29-41. (PMID: 11165421)

35. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vschlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackTrial (ALLHAT). JAMA 2000;283:1967-1975. (PMID: 10789664)

36. Djojonegoro* BM, Aday LA, Williams AF, Ford CE. Area income as a predictor ofpreventable hospitalizations in the Harris County Hospital District, Houston. TexasMedicine 2000; 96:58-62.

37. Cooksley* CD, Hwang LY, Waller DK, Ford CE. HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data. International Journal ofSTD & AIDS 1999; 10: 795-802.

38. Proschan M, Davis B, Cutler J Ford C, Furberg C, Grimm R, and Oparil S, for the ALLHATResearch Group. ALLHAT and calcium channel blockers. American Journal ofHypertension 1997;10:142-143. (Letter to the Editor) (PMID: 9008261)

39. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm R, LaRosaJ, Whelton PK, Perry HM, Alderman M, Ford CE, Oparil S, Francis C, Proschan M, PresselS, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal ofHypertension 1996; 9:342-360.

40. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, StamlerJ. Blood pressure and incidence of end-stage renal disease in men. New England Journalof Medicine 1996; 334:13-18.

41. Walker WG, Ford C. At risk nephrons and the decline in renal function in response totreatment of hypertension. Transactions of the American Clinical and ClimatologicalAssociation 1995; 107:134-145.

42. Tyroler HA, Ford CE. Serum cholesterol and coronary heart disease risk in female andolder hypertensives: the experience under usual community care in the HDFP. AnnEpidemiol 1992; 2:155-160.

43. Walker WG, Ford CE, Cutler JA, Shulman NB, for the HDFP Research Group. Change inrenal function during treatment in the Hypertension Detection and Follow-up Program(HDFP). Am J Hyperten 1992; 5:58a.

44. Stamler R, Ford CE, Stamler J. Why do lean hypertensives have higher mortality ratesthan other hypertensives? Findings from the Hypertension Detection and Follow-upProgram. Hypertension 1991; 17:553-564.


45. Cooper SP, Ford CE, Hardy RJ, Davis BR, Hawkins CM, Labarthe DR. Letter to the Editorregarding “Goals of antihypertensive therapy: is there a point beyond which pressurereduction is dangerous?” American Journal of Hypertension 1990; 3:733-734.

46. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. Theprognostic value of serum creatinine and the effect of treatment of hypertension on renalfunction. Results from the Hypertension Detection and Follow-up Program. Hypertension1989; 13(Suppl I):80-93.

47. HDFP Cooperative Group. Persistence of reduction in blood pressure and mortality ofparticipants in the Hypertension Detection and Follow-up Program. JAMA 1988; 259:2113-2122.

48. Schneider KA, Heyden S, Ford C. Failure to reduce cholesterol as explanation for thelimited efficacy of antihypertensive treatment in the reduction of CHD. Evidence from theHDFP. Nefron 1987; 47(Suppl 1):104-107.

49. Ford CE, Langford HG, Palmer M. Recruitment in the Hypertension Detection and Follow-up Program. Controlled Clinical Trials 1987; 8:54S-67S.

50. Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM. The HDFP design, methods,and baseline characteristics and blood pressure response of the study population. Progress in Cardiovascular Disease 1986; 29(Suppl 1):11-28.

51. HDFP Cooperative Group. Implications of the HDFP. Progress in Cardiovascular Disease1986; 29(Suppl 1):3-10.

52. HDFP Cooperative Group. Results and implications of the Hypertension Detection andFollow-up Program. Progress in Cardiovascular Disease 1986; 29(Suppl 1):1-124.

53. Curb JD, Ford C, Pressel S, Palmer M, Babcock C, Hawkins CM. Ascertaining vital statusthrough the National Death Index and the Social Security Administration. Am J Epidemiol1985; 121:754-766.

54. Maxwell MH, Ford CE. Cardiovascular morbidity and mortality in HDFP patients 50-69years old at entry. J of Cardiovascular Pharmacology 1985; 7(Suppl 2):5-9.

55. HDFP Cooperative Group. Mortality findings for stepped-care and referred-careparticipants in the HDFP, stratified by other risk factors. Preventive Medicine 1985;14:312-335.

56. HDFP Cooperative Group. Five-year findings of the HDFP. Prevention and reversal of leftventricular hypertrophy with antihypertensive drug therapy. Hypertension 1985; 7:105-112.

57. HDFP Cooperative Group. The effect of antihypertensive drug treatment on mortality inthe presence of resting electrocardiographic abnormalities at baseline: the HDFPexperience. Circulation 1984; 70:996-1003.

58. HDFP Cooperative Group. Effect of stepped care treatment on the incidence ofmyocardial infarction and angina pectoris. Five-year findings of the HDFP. Hypertension1984; 6(Suppl I):198-206.

59. HDFP Cooperative Group. The Hypertension Detection and Follow-up Program. Baselinecharacteristics of the enumerated, screened, and hypertensive participants. Hypertension1983; 5(Suppl IV):1-200.

60. Curb JD, Ford C, Hawkins CM, Smith EO, Zimbaldi N, Carter B, Cooper C. TheCoordinating Center in a clinical trial: the HDFP. Controlled Clinical Trials 1983; 4:171-186.


61. Curb JD, Hawkins CM, Ford C. Should mild hypertension be treated. (Letter) N Engl J Med1982; 307:1522-1523.

62. HDFP Cooperative Group. Five-year findings of the Hypertension Detection and Follow-upProgram. III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982; 247:633-638.

Books, Chapters, Miscellaneous

Wright JT Jr, Probstfield JL, Cushman WC, Pressel S, Cutler JA, Davis BR, Einhorn PT,Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR,Alderman MH, for the ALLHAT Collaborative Research Group. ALLHAT findings revisitedin the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med2009; 169:1810-1811. Letter

Davis BR, Ford CE. The Hypertension Detection and Follow-up Program, in Clinical Trials inHypertension, 2001; pp:27-60, Henry R. Black (Ed.), Marcel Dekker, New York, New York.

Davis BR, Ford CE. Annotated Bibliography of Epidemiological Methods of CardiovascularResearch. Chapter 12: Blood Pressure. Committee on Criteria and Methods of theCouncil on Epidemiology, American Heart Association, 1994.

Canfield MA, Phelps A, Falletti R, Begley C, Schreyer G, Meade D, Ford C, Reynolds K for theHarris County Epidemiology Advisory Subcommittee. Epidemiologic Data for the Houston-Area HIV Plan. November 1991.

ABSTRACTS AND PRESENTATIONS:

The utility of post-trial follow-up of participants– the Antihypertensive and Lipid-LoweringTreatment to Prevent Heart Attack Trial experience. Pressel S, Davis BR, Ford C, PillerLB, Simpson LM, Baraniuk S, for the ALLHAT Collaborative Research Group. (Presentedby Sara Pressel at the 31st Annual Meeting of the Society for Clinical Trials, May 16-18,2010, Vancouver, Canada.)

Alderman M, Calhoun D, Cushman W, Davis B, Eckfeldt J, Einhorn P, Ford C, Franklin S,Furberg C, Ong S, Oparil S, Papademetriou V, Piller L, Probstfield J. Relationship of 1year hypokalemia incidence to clinical outcomes in the Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (Presented by MichaelAlderman at American Heart Association Scientific Sessions 2006, November 12-15, 2006,Chicago, Illinois.)

Koers EM, Day RS, Ford C, Kelder S, Tisone C. Social and cultural determinants of immigranthealth in the context of a developing country. (Presented November 6, 2006, by ErinKoers at the 134th Annual Meeting & Exposition of the American Public Health Association,November 4-8, 2006, Boston, Massachuset.)

Crider NM, Rosenau P, Swint JM, Franzini L, Carson A, Ford CE. Impact of hypertension andhypertension guidelines on industrialized and developing nations. (Presented by NancyCrider at the 134 Annual Meeting & Exposition of the American Public Health Association,th

November 4-8, 2006, Boston, Massachuset.)

Haywood J, Ford CE. Influence of atrial fibrillation on incidence and outcome of stroke inALLHAT. (Presented by Julian Haywood at American Society of Hypertension Meeting,May 17-20, 2006, New York, New York.)


Alderman MH, Piller LB, Ford CE, Cushman W, Calhoun D, Davis BR, Eckfeldt J, Einhorn P,Franklin S, Furberg C, Ong S, Oparil S, Papademetriou V, Probstfield J. The occurrenceand clinical impact of hypo- and hyperkalemia in ALLHAT. (Presented by Jeff Probstfieldat the European Society of Cardiology, September 7, 2005, Stockholm, Sweden.)

Piller L, Ford C, Davis B, Nwachuku C, Black H, Oparil S, Gappy S, Retta T, Probstfield J. Angioedema in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackTrial (ALLHAT). (Presented by Linda Piller at 20th Annual Scientific Meeting of theAmerican Society of Hypertension, May 14-18 [16], 2005, San Francisco, CA.)

Haywood J, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. Atrial Fibrillationin ALLHAT.(Presented by Julian Haywood at the International Society on Hypertension inBlacks Meeting, June 13-16, 2004, Detroit, Michigan.) Abstract: Ethnicity and Disease2004; 14:??-??.

Cushman WC, Ford CE, Einhorn P, Wright JT, Preston RA, Davis BR, Basile JN. Bloodpressure control by randomized drug group in ALLHAT. (Presented by Bill Cushman at the19th Annual Meeting of the American Society of Hypertension, May 18-22, 2004, NewYork, NY.) Abstract: Am J Hypertension 2004; 17:S30.

Haywood LJ, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. Atrial fibrillationat baseline and during follow-up in ALLHAT. (Presented by C Ford at the 76th AnnualScientific Sessions of the American Heart Association, November 9-12, 2003, Orlando,Florida.) Abstract: Circulation 2003; 108(Suppl IV):IV-371.

Ford CE. Blood pressure control: Success of a structured treatment program. (Presented at aspecial UT Health Science Center at Houston symposium held in the School of PublicHealth Auditorium, September 19, 2003.)

Ford CE, Margolis KL, Piller L, Cushman WC, Wright JT, Colon PJ, for the ALLHATCollaborative Research Group. Blood pressure control in Hispanics in the Antihypertensiveand Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (Presented by CEFord at the 15th Scientific Meeting of the Inter-American Society of Hypertension, April 27-30, 2003, San Antonio, Texas.)

Ford CE. ALLHAT Results: Diuretic best for treating hypertension. (Presented at the 2003SPH Faculty and Student Research Day, The University of Texas Health Science Center atHouston, School of Public Health, March 21, 2003.)

Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black H. Gene-drug interactions in thecontext of an active-controlled trial. (Presented by BR Davis at the 2002 Joint StatisticalMeetings of the American Statistical Association, the International Biometric Society(ENAR and WNAR), the Institute of Mathematical Statistics, and the Statistical Society ofCanada, August 13, 2002, New York, New York.)

Ford C. Conducting clinical trials in private practices: What works and what doesn’t. (Presented by CE Ford at the 22 Annual Meeting of the Society for Clinical Trials, Maynd

20-23, 2001, Denver, Colorado.) Abstract: Controlled Clinical Trials 2001; 22:17S.

Margolis K, Piller L, Lewis C, Goff D, Cushman W, Wright J, Colon P, Ford C. Blood pressurecontrol in Hispanic participants in ALLHAT. (Presented by K Margolis at the AmericanHeart Association Conference on Cardiovascular Disease Epidemiology and Prevention,March 2, 2001, San Antonio, Texas). Abstract: Circulation 2001; 103:1348.

Ford CE, Wright JT. Major cardiovascular events in hypertensive patients randomized todoxazosin vs. chlorthalidone, with additional data on Hispanics. (Presented by CE Ford atthe Fifth Meeting of the ALLHAT Investigators, September 16, 2000, Orlando, Florida.)


Colon PJ, Wright JT, Ford CE, Cuttler JA, for the ALLHAT Collaborative Research Group. Cardiovascular disease rates in Hispanic and Caribbean hypertensives receiving doxazosinand chlorthalidone in the ALLHAT. (Presented by P. Colon at the Joint Meeting of theInternational Society for Hypertension in Blacks and the 15 Annual Interdisciplinaryth

Conference on Hypertension and Related Risk Factors in Ethnic Populations, July 15-18,2000, Las Croabas, Puerto Rico.) Abstract: Ethnicity and Disease 2000; 10:315-316.

Bettencourt J, Ford CE. Differences in adherence patterns of ALLHAT participants. (Presentedby J Bettencourt at the 21 Annual Meeting of the Society for Clinical Trials, Toronto,st

Canada, April 16-19, 2000.) Abstract:Controlled Clinical Trials 2000; 21:105S-106S.

Kimmel B, Ford C, Piller L, Pressel S. Importance of assessing vital status of participants andcollecting endpoint data in clinical trials (ALLHAT study). (Presented by B. Kimmel at the1999 UT-HHSC Research Day, October 8, 1999, Houston, Texas.)

Haywood J, Crow R, Ford C, Davis B, for the ALLHAT Research Group. Atrial fibrillation in theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial at baseline. (Presented by J. Haywood at the International Society on Hypertension in Blacks (ISHIB),July 11-13, 1999, Toronto, Canada. Abstract: pending.

Ford CE. From where do all those health statistics come. (Presented at the 7 Annualth

Summer Conference on Opportunities in Public Helath, May 26-28, 1999, in Houston,Texas.)

Ford CE. The Silent Killer - Hypertension; The Disease Control Module at UT-HSPH. (Presented at the 7 Annual Summer Conference on Opportunities in Public Helath, Mayth

26-28, 1999, in Houston, Texas.)

Margolis KL, Cushman WC, Wright JT, Grimm RH, Ford CE, Cutler JA for the ALLHATResearch Group. Racial differences in blood pressure control in the Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial. (Presented by KL Margolis at the22 Annual Meeting of the Society for General Internal Medicine, San Francisco,nd

California, April 30, 1999.)

Davis BR, Ford CE, Boerwinkle E, Atwood L, Arnett D. Design and analysis considerations forassessing gene-treatment interactions in a clinical trial. (Presented by BR Davis at the1998 Joint Statistical Meetings, August 9, 1998, in Dallas, Texas.)

Nwachuku CE, Cutler J, Payne GH, Proschan MA, Ford CE, Davis BR, Pressel S, Hawkins CM,for the ALLHAT Research Group. Regional differences in attainment of goal bloodpressure (BP) among treated hypertensives in the United States. (Presented by CENwachuku at the 16 Meeting of the International Society of Hypertension (ISH), Juneth

1998, Amsterdam, Netherlands.) Abstract: J Hypertension 1998; 16(Suppl 2):97.

Pressel S, Morvillo C, Kimmel B, Davis B, Ford C, Egan D. Patient recruitment in theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (Presented by S Pressel at the 19 Annual Meeting of the Society for Clinical Trials, Mayth

17-20, 1998 Atlanta, Georgia.) Abstract: Controlled Clinical Trials 1998; 19:46S-46S.

Nwachuku CE, Probstfield JL, Ford CE, Payne GH, Grimm RH for the ALLHAT ResearchGroup. Visit (Vad) and medication (Mad) adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Effect of age and otherfactors. (Presented by CE Ford at the 13 Scientific Meeting of the American Society ofth

Hypertension, May 13-16, 1998, New York, NY.) Abstract: Am J Hypertension 1998;11:??A.


Cushman WC, Black HR, Probstfield JL, Holland JJ, Hamilton BP, Margolis K, Nwachuku CE,Payne GH, Ford CE for the ALLHAT Research Group. Blood pressure control in theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (Presented by WC Cushman at the 13 Scientific Meeting of the American Society ofth

Hypertension, May 13-16, 1998, New York, NY.) Abstract: Am J Hypertension 1998;11:17A.

Cooksley CD, Hwang LY, Waller K, Ford CE. HIV-related malignancies: A community basedstudy using a linkage of cancer registry and HIV registry data. (Presented by CD Cooksleyat the Second National AIDS Malignancy Conference, April 6-8, 1998, Bethesda,Maryland.) Abstract: J of Acquired Immune Syndrome and Human Retro Virology

Davis BR, Hawkins CM, Cutler JA, Payne G, Ford CE, Pressel S, Gordon D, Nwachuku C,Wright J, Cushman W, Grimm R for the ALLHAT Research Group. ALLHAT: The largestclinical trial in hypertension ever undertaken. (Presented by BR Davis at the 6thInternational Symposium on Hypertension in the Community: Screening, Investigation, andTherapy, February 8-11, 1998, Geneva, Switzerland.)

Grimm RH Jr, Davis BR, Ford C, Alderman MH, Black HR, Cushman WC, DeQuattro V,Papademetriou. The Antihypertensive and Lipid-Lowering Treatment to Prevent HeartAttack Trial (ALLHAT): The largest clinical trial in hypertension ever undertaken. (Presented by RH Grimm at the 70 Scientific Sessions of the American Heart Association,th

November 9-12, 1997, Orlando, Florida.) Abstract: Circulation 1997; 96:I-278.

Davis BR, Proschan M, Ford CE, for the ALLHAT Research Group. Statistical issues in a large,simple trial of antihypertensive and lipid-lowering treatments. (Presented by BR Davis atthe American Statistical Association Meeting; Chicago, IL; August 4-18, 1996.)

Davis B, Proschan M, Ford CE, for the ALLHAT Research Group. Statistical designconsiderations for a large, simple trial of antihypertensive and lipid lowering treatments. (Presented by B. Davis at the International Biometric Conference; Amsterdam,Netherlands; July 1-5, 1996.)

Ford CE. The Silent Killer - High Blood Pressure: Evolution of a Public Health Problem. (Presented at the 4 Annual Summer Conference on Opportunities in Public Helath, Mayth

28-31, 1996, in Houston, Texas.)

Harrist RB, Ford CE. Opportunities in Biostatistics and Public Health for Science Majors. (Presented by C.E. Ford at the 1995 Joint Statistical Meetings, August 15, 1995, inOrlando, Florida.)

Ford CE. Biometric applications in public health. (Presented at the 1995 Conference onCareer Opportunities in Biostatistics and Public Health for Science Majors at St. Mary’sUniversity, May 19, 1995 in San Antonio, Texas.)

Pressel S, Egan D, Ford CE, Walsh S, Miertschin N. Selection of clinical sites for theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (Presented by S. Pressel at the 16th Annual Meeting of the Society for Clinical Trials, April30 - May 3, 1995, Seattle, Washington.) Abstract: Controlled Clinical Trials 1995; 16:106S.

Davis BR, Cutler JA, Gordon D, Furberg C, Wright J, Cushman W, Grimm R, LaRosa J,Whelton P, Manolio T, Perry HM, Alderman M, Ford CE, Oparil S, Francis C, Proschan M,Pressel S, Black H, Hawkins CM for The ALLHAT Research Group. Rationale and Designof the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT). (Presented by B.R. Davis at the 35th Annual Conference on CardiovascularDisease Epidemiology and Prevention, March 1995.)


Walker WG, Ford CE, Cutler JA, Shulman NB. Change in Renal Function During Treatment inthe Hypertension Detection and Follow-up Program (HDFP). (Presented by W.G. Walkerat the Annual Meeting of the American Society of Nephrology, October, 1994.)

Davis BR, Moyé LA, Ford CE, Wun CC. Beyond traditional stochastic curtailment. (Presentedby B. R. Davis at the International Biometric Conference (IBC), August, 1994, in Hamilton,Ontario, Canada.

Davis BR, Moyé LA, Ford CE, Wun CC. Stochastically curtailing several types of tests. (Presented by B. R. Davis at the Eastern North American Region (ENAR) of the BiometricSociety Spring Meeting, April 10-13, 1994, Cleveland, Ohio.)

Klag MJ, Whelton PK, Neaton JD, Randall B, Ford CE, Brancati FL, Shulman N, Stamler J. Race and Incidence of ESRD: A Prospective Study. (Presented by M. J. Klag at the 34thAnnual Conference on Cardiovascular Disease Epidemiology and Prevention, March 16-19, 1994, in Tampa, Florida.)

Klag MJ, Whelton PK, Neaton JD, Randall B, Ford CE, Brancati FL, Shulman N, Stamler J. Blood pressure and incidence of ESRD in men: a prospective study. (Presented by M. J.Klag at the 34th Annual Conference on Cardiovascular Disease Epidemiology andPrevention, March 16-19, 1994, in Tampa, Florida.)

Walker WG, Ford CE, Cutler JA, Shulman NB. Change in Renal Function During Treatment inthe Hypertension Detection and Follow-up Program (HDFP). (Presented by W.G. Walkerat the 14th Scientific Meeting of the International Society of Hypertension, June 14-19,1992, in Madrid, Spain.) Abstract: Journal of Hypertension 1992; 5:58a.

Ford CE. The effect of antihypertensive drug treatment on combined morbidity and mortality inblacks and whites. (Invited presentation by C.E. Ford at the 7th InternationalInterdisciplinary Conference on Hypertension in Blacks, May 28, 1992, in Atlanta, Georgia.)

Ford CE, Davis BR, Hawkins CM, Stamler J, Langford HG, Daugherty SA, Borhani NO, CurbJD, Payne GH, Remington RD. The effect of treatment on combined trial endpoints in theHypertension Detection and Follow-up Program (HDFP). (Presented by C.E. Ford at the31st Annual Conference on Cardiovascular Disease Epidemiology, March 14, 1991, inOrlando, Florida.) Abstract: Circulation 1991; 83: 716.

Curb JD, Pressel S, Daugherty S, Schneider K, Payne G, Ford C. The relationship of whiteblood cell count to total and coronary heart disease mortality. (Presented by Sara Presselat the 63rd Scientific Sessions of the American Heart Association, November 1990, inDallas, Texas.) Abstract: Circulation 1990; 82(Suppl III): III-616.

Stamler R, Ford CE, Stamler J. Why do lean hypertensives have higher mortality rates thanaverage weight hypertensives? Findings from the Hypertension Detection and Follow-upProgram. (Presented by Rose Stamler at the 63rd Scientific Sessions of the AmericanHeart Association, November 1990, in Dallas, Texas.) Abstract: Circulation 1990; 82(SupplIII): III-554.

Moorman PG, Ford CE, Tyroler HA. Educational level and all-cause mortality in the HDFP trialand Post-Trial Surveillance Study (PTSS). (Presented by P.G. Moorman at the 13thScientific Meeting of the International Society of Hypertension, June 1990, in Montreal,Canada.)

Davis BR, Ford CE, Mahboob S. Short-term projections of AIDS incidence in Texas.(Presented by Barry Davis at the 1990 Conference of Texas Statisticians, March 23, 1990,Houston, Texas.)


Ford CE, Shulman NB. Prevalence, incidence, prognostic value, and treatment implications ofrenal disease in a hypertensive population. (Presented by C.E. Ford at the NHLBIWorkshop on Antihypertensive Drug Treatment: The Benefits, Costs, and Choices,Bethesda, Maryland, June 11-12, 1987.)

HDFP Cooperative Group. Eight-year follow-up of participants in the HDFP: Persistence ofreduction in blood pressure and mortality in a treated hypertensive population. (Presentedby C.E. Ford at 52nd Annual Scientific Assembly of the American College of ChestPhysicians, San Francisco, California, September 25, 1986.) Abstract: Chest 1986;89:496S. (Also presented by N.O. Borhani at the 11th Congress of the InternationalSociety of Hypertension, Heidlberg, Federal Republic of Germany, September 1986.)

Schneider KA, Heyden S, Ford CE. Failure to reduce cholesterol as explanation for limitedefficacy of antihypertensive treatment in the reduction of CHD. Evidence from the HDFP. (Presented by K.A. Schneider at the Satellite Symposium to the 11th Congress of theInternational Society of Hypertension, Titisee, Federal Republic of Germany, September1986.)

Daugherty SA, Curb JD, Ford CE, Hawkins CM, Langford HG, Pressel S, Taylor JO. Eight-yearfollow-up of participants in the HDFP. Persistence in the reduction in blood pressure andmortality in a treated hypertensive population. (Presented by S.A. Daugherty at the 25thConference of the AHA Council of Epidemiology, Tucson, Arizona, March 7, 1985.)

Langford HG, Ford CE, Blaufox MD. Is hypertension worse in blacks? Comparison ofcreatinine levels at equal blood pressures; effect of potassium. (Presented by H.G.Langford at the 17th Annual Meeting of the American Society of Nephrology, New Orleans,January 31, 1985.)

Maxwell MH, Ford CE. Cardiovascular morbidity and mortality in HDFP patients 50-69 yearsold at entry. (Presented by M.H. Maxwell at Satellite Symposium on CardiovascularMorbidity and Large Arteries in Hypertension, Paris, France, June 1984.)

Curb JD, Palmer M, Pressel S, Ford CE, Zimbaldi N, Babcock C, Jennings P, Hawkins CM. Ascertaining vital status through the National Death Index and the Social SecurityAdministration. (Presented by J.D. Curb at the 4th Annual Meeting of the Society forClinical Trials, St. Louis, Missouri, May 8, 1983.) Abstract: Controlled Clinical Trials 1983;4:154.

Curb JD, Hawkins CM, Smith EO, Zimbaldi N, Ford CE, Carter B, Cooper C. The CoordinatingCenter in a clinical trial. (Presented by C.E. Ford at the 2nd Annual Meeting of the Societyfor Clinical Trials, San Francisco, California, May 12, 1981.) Abstract: Controlled ClinicalTrials 1981; 2:83.

Blaufox MD, Langford HG, Ford CE. End-organ damage in hypertension and medicationrequirements for control of blood pressure. (Presented by M.D. Blaufox at the 52ndScientific Sessions of the American Heart Association, Anaheim, California, November1979.)

Ford CE. Monitoring clinical trial study data acquisition by means of an interactive informationmanagement system. (Presented by C.E. Ford at the Fourth Annual Meeting of PersonnelInvolved in Coordinating Collaborative Clinical Trials, Chapel Hill, North Carolina, May 19-20, 1977.)


THESIS AND DISSERTATION COMMITTEES (n=76):

Anthony John Orencia, MS, Epidemiology, May 1988: Occurrence and risk factors of chronic

bronchitis in a cohort of 10,940 hypertensives. Thesis Committee Member

William David Hart, MPH, Population Studies, August 1990: Weekly food expenditures as

affected by age group, income group and family size. Thesis Committee Member

Melissa D. Tonn, MPH, Occupational Health and Aerospace Medicine, May 1991: Urgent-

ambulatory-occupational health care center at the Texas Medical Center. Thesis Committee

Member

Valerie Kay Dahlberg, MPH, Disease Control, August 1991: A cross sectional population survey

to assess the prevalence of blood donation in Bryan and College Station, Texas. Thesis

Committee Member

Denise Kaye Elizabeth Smith, MPH, Community Health Practice, August 1991: An evaluation of

prenatal patient satisfaction with care provided in an urban public health clinic. Thesis

Committee Member

Manel Pladevall-Vila, MS, Epidemiology, May 1992: Oral contraceptives and the risk of

rheumatoid arthritis: a new meta-analysis of conflicting studies and a review of conflicting meta-

analyses with special emphasis on the analysis of heterogeneity.

Susan Louise McFarland, MPH, Occupational Health and Aerospace Medicine, August 1992:

Concentrations of selected chemical contaminants of space shuttle crew cabins: implications

regarding astronaut health during extended duration missions. Thesis Committee Member

Barbara L. Becker, MPH, Health Services Organization, August 1993: Health insurance, what

you have and what you want: A study of the health benefit trust of the United Way of the Texas

Gulf Coast. Thesis Committee Member

Rebecca J. Pack, PhD, Epidemiology May 1994: Incidence of breast cancer in first-degree

female relatives of men with newly diagnosed prostate cancer. Dissertation Committee

Member

Rebecca T. Kirkland, MPH, Health Services Organization, May 1995: Competencies in the

medical curriculum: a descriptive survey of attitudes of teaching faculty at Baylor College of

Medicine. Thesis Committee Member

Mutuku A. Mwanthi, PhD, Environmental Science, May 1996: Presence of three pesticides in

rural drinking water sources in Kenya. Dissertation Committee Member

Wendy C. Goldstein, MPH, Health Services Organization, December 1996: An examination of

attitudes, awareness and prevalence of "living wills" among three populations of graduate

students. Thesis Committee Member

Joanna Kay Napp, MPH, Health Services Organization, December 1996: New dimensions in

genetics, prenatal screening and informed consent: a comprehensive literature review and

expert opinion analysis. Thesis Committee Member


Suzanne Rochelle Taylor, MPH, Health Promotion/Health Education, December 1996: Bone

marrow registry and donation: relevant behavioral beliefs among African Americans. Thesis

Committee Member

Catherine Donery Cooksley, DrPH, Disease Control, May 1997: HIV-related malignancies: A

community based study using a linkage of cancer registry and HIV registry data. Dissertation

Committee Member

Ashraful Hoque, PhD, Epidemiology, May 1997: Epidemiology of secondary leukemia with

reference to chromosomal abnormalities. Dissertation Committee Member

Baby Mayangsari Djojonegoro, MPH, Health Services Organization, December 1997:

Ambulatory care sensitive hospitalizations in Harris County Hospital District. Thesis Committee

Member

Aftad Hashim, MPH, Disease Control, December 1997: Aids trends and proposed interventions

in Houston metropolitan statistical area. Advisor & Thesis Supervisor

Myrna Jane Meyer Khan, PhD, Biostatistics, December 1997: Statistical characterization and

development of summary measures of non-normal distributions of nuclear morphometry data

from prostate cancer cells for use as prognostic indicators. Dissertation Committee Member

Peggy Lynn, MS, Biometry, December 1997: An analysis of hospital outcomes in female PTCA

patients. Advisor & Thesis Supervisor

Todd Young Brandt, PhD, Epidemiology, May 1998: The cellular and molecular involvement of

glutathione in cisplatin-induced apoptosis. Dissertation Committee Member

Sandra A. Acholonu, MPH, International and Family Health, December 1998: Maternal obesity:

is it a risk factor for major birth defects? Thesis Committee Member

Nicole Larson, MS, Biological Sciences, May 1999: Molecular epidemiology of hypertension in

African Americans. Thesis Committee Member

Melissa D'aun Jordan, MPH, Occupational and Environmental Health/Aerospace Medicine,

December 1999: An initial health and safety assessment of clinics affiliated with an academic

health science center. Thesis Committee Member

Mary Ellen Trail Ross, DrPH, Health Services Organization , May 2001: Stress and coping in

African American grandparents who are raising their grandchildren. Dissertation Committee

Member

Judith Bettencourt, MPH, Disease Control, August 2001: Comparing adherence among

ALLHAT participants recruited through different methods. Advisor and Thesis Supervisor

Rachel A. Gorham, MS, Biostatistics, December 2001: Statistical validation of a commonly used

method for personnel dosimetry issuance determinations. Advisor & Thesis Supervisor

David Olsen, PhD, Biostatistics, December 2001: Latent class analysis and extensions with

latent and manifest covariates. Dissertation Committee Member


Jeffrey S. Godell, MPH, Health Promotion/Health Education, May 2002: A formative evaluation

of LiveHelp, a pilot program to provide cancer information via instant messaging. Thesis

Committee Member

Stacy A. Hemby, MPH, Disease Control, May 2002: Comparison of two immunization rate

assessment methods: Chart review vs. computerized billing data. Advisor and Thesis

Supervisor

Samidha Worah, MPH, Disease Control, May 2002: The effect of hormone replacement therapy

on immune response. Advisor

Judy M. Kallus, MPH, Disease Control, December 2002: Servings of fruit, juice, and vegetables

and percentage of fat consumed among foods prepared at and away-from-home by low income

African-American and Mexican-American adolescents. Thesis Committee Member

Cari J. Norwood, MPH, Health Promotion/Health Education, May 2003: Sales of competitive

foods at thirty-three middle schools in the Houston Independent School District. Thesis

Committee Member

Scott Dwayne Rollins, MS, Epidemiology, August 2003: The effect of coronary artery disease in

aortic valve replacement using porcine bioprosthesis. Thesis Committee Member

Bridget Alexis Kenworthy, MPH, Disease Control, December 2003: A point prevalence study on

the misuse of indwelling urinary catheters and urinary tract infections in the long-term acute

care setting. Advisor and Thesis Supervisor

Mala Pande, MPH, Disease Control, December 2003: Phenol sulphotransferase sult1a1

polymorphism and age of onset of colorectal cancer. Thesis Committee Member

Tonya A. Khan, MPH, Disease Control, May 2004: Smoking and oral contraceptives: how do

they influence premenopausal breast cancer estrogen receptor status? Advisor and Thesis

Supervisor

Byron Oujesky, MS, Epidemiology, May 2004: West Nile virus sero-prevalence population

survey. Thesis Committee Member

Tamra Meyer, MPH, Epidemiology and Disease Control, August 2004: Seroprevalence of West

Nile virus in Houston’s homeless population. Advisor

Lingling (Linda) Gao, MPH, Disease Control, May 2005: Influences of parents and peers on

adolescents’ smoking intention. Advisor

Larry Morning Star, DrPH, Community Health Practice, May 2005: Chronic volatile substance

abuse among the adult Kickapoo traditional tribe of Texas: Disease and disability profiles;

neuropsychosocial consequences; and social implications for treatment. Dissertation

Committee Member

Thien Vu, MPH, Health Promotion/Health Education, May 2005: Language barrier and maternal

participation in meeting children's health care needs in a Vietnamese population. Thesis

Committee Member


Wuan-Szu (Nancy) Wang, PhD, Biostatistics, May 2005: Analysis of outliers for logistic

regression based on predicted probability and winsorized observations. Dissertation Committee

Member

Tao Wang, MS, Biostatistics, May 2005: Reduced glomerular filtration rate and the risk of death

in hypertensive participants in the HDFP study. Advisor and Thesis Supervisor

Danielle R. Litofsky, MPH, August 2005: The role of dietary and supplemental selenium in the

risk of prostate cancer: a case-control analysis. Thesis Committee Member

Erin M. Koers, MPH, Epidemiology and Disease Control, December 2005: Social and cultural

determinants of immigrant health in the context of a developing country. Advisor

Liqian Liu, MS, Epidemiology, December 2005: Long-term survival after radical prostatectomy

or other treatments in older men with early-stage prostate cancer. Thesis Committee Member

Manisha Jhamb, MPH, Disease Control, May 2006: Effect of urinary tract diseases on bladder

cancer risk: a case control study. Advisor

Esther Enu, MPH, Epidemiology, December 2006: Biomarkers as predictors of progression

rates in Alzheimer disease. Advisor & Thesis Supervisor

Kimberly Lockhart, MPH, Disease Control, December 2006: A comparison of characteristics of

illegal drug users and their hepatitis B and HIV risks from two urban neighborhood community

samples in Houston, Texas. Thesis Committee Member

Kristina Riis Dahlstrom, MS, Epidemiology, May 2007: The association of sexual behavior with

oropharyngeal cancer and correlations with HPV-16 serologic status false. Thesis Committee

Member

Shyam Mohan Dang, MS, Epidemiology, May 2007 Leptin: Growth factor for melanoma cells.

Thesis Committee Member

Manjunath M. Shetty, MPH, Disease Control, May 2007: The effect of blood pressure control on

all-cause mortality in the HDFP. Thesis Advisor

Geetika Srivastava, MS, Epidemiology, May 2007: Risk of spontaneous intracranial hemorrhage

in patients with non-small cell lung cancer and brain metastasis. Thesis Committee Member

Sireen Mahmoud Alkhaldi, PhD, Environmental and Occupational Health Sciences, May 2008:

Maternal health care utilization in rural Jordanian villages: Patterns and predictors. Dissertation

Committee Member

Vishal Rana, MS, Epidemiology, May 2008: The epidemiology of hepatitis B and hepatitis C

virus infection among college students who are not US/Canadian born in Houston. Thesis

Committee Member

Alisa Acosta, MPH, Disease Control, August 2008: Association of left ventricular hypertrophy

and stage of hypertension by ambulatory blood pressure monitor. Advisor & Thesis Supervisor


Paresh Prabhakar Kamat, MPH, Disease Control, August 2008: Is body mass index associated

with Barrett esophagus : A systematic literature review. Advisor & Thesis Supervisor

Dhanasekaran Kotilingam, MS, Biological Sciences, August 2008: Prognostic factors in

desmoid tumors. Thesis Committee Member

Nazila Barahmani, MS, Epidemiology, December 2008: Prior history of atopy or autoimmunity

increases risk for alopecia areata. Thesis Committee Member

Ashwini Mhatre, MS, Epidemiology, December 2008: The association between diabetes and

hepatitis C: A systematic review of epidemiological evidence. Thesis Committee Member

Tamra Elaine Meyer, PhD, Epidemiology, December 2008: Diabetes genes and risk of prostate

cancer in the atherosclerosis risk in communities study. Dissertation Committee Member

Aroub Ayham Khleif, PhD, Epidemiology, May 2010: Pregnancy intention, intimate partner

violence, and the use of prenatal care in Jordan. Dissertation Committee Member

Debra L. Canter, MS, Epidemiology, August 2010: Metabolic syndrome and cardiovascular

mortality among participants of the Hypertension Detection and Follow-Up Program. Thesis

Committee Member

Susan Michelle Rossi, MS, Epidemiology, August 2010: Genome-wide association study of

LDL-cholesterol over ApoB ratio. Thesis Committee Member

Jennifer Ziervogel, MS, Biostatistics, August 2010: Dietary patterns and risk of pancreatic

cancer in a hospital-based case-control study. Advisor

Kok Yan Ling, MPH, Environmental and Occupational Health Sciences, December 2010:

Demographic analysis of certified industrial hygienists (CIH) with the use of survival analysis

techniques. Thesis Committee Member

Navid Sadeghi, MS, Epidemiology, December 2010: Retrospective cohort study to determine

the effect of metformin on survival of diabetic patients with pancreatic adenocarcinoma. Thesis

Committee Member

Selome Ayele Lemessa, MPH, Environmental and Occupational Health Sciences, May 2011: A

feasibility study for assessing building occupants’ indoor air quality expectations compared to

nationally recognized standards. Thesis Committee Member

Marape Marape, PhD, Epidemiology, May 2011: Predictors of HIV-1 slow progression among

vertically infected children in Botswana. Dissertation Committee Member

Diana Martínez, PhD, Epidemiology, May 2011: Burden of invasive pneumococcal disease in

Harris County, Texas (2003-2010) and the implication for enhanced public health surveillance of

isolates. Dissertation Committee Member

Duc Tan Minh Nguyen, PhD, Epidemiology, May 2011: Tuberculosis in HIV-infected individuals

in Ho Chi Minh City, Vietnam. Dissertation Committee Member


Parikshit S Sharma, MPH, Epidemiology and Disease Control, May 2011: Early identification of

symptomatic aortic stenosis using echocardiographic data. Advisor & Thesis Supervisor

Min Yi, PhD, Biostatistics, May 2011: Bayesian and survival model for tumor relapse status and

disease-specific survival, with applications to breast cancer. Advisor

Victoria Friedel, PhD, Epidemiology, August 2011: Longitudinal and logistic analysis of

candidate genes, hormone levels, and physical maturation related to pubertal events in

children. Dissertation Committee Member

Heta Javeri, MPH, Epidemiology and Disease Control, August 2011: Capstone Course. Advisor

curriculum vitae › cv › ford.pdf · 2011-10-04 · october 4, 2011 curriculum vitae name:...

Documents